Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.

Bansal, Radhika; Baksh, Mizba; Larsen, Jeremy T.; Hathcock, Matthew A.; Dingli, David; Stewart, A. Keith; Kapoor, Prashant; Kourelis, Taxiarchis; Hayman, Suzanne R.; Warsame, Rahma M.; Fonseca, Rafael; Bergsagel, P. Leif; Ailawadhi, Sikander; Kumar, Shaji K.; Lin, Yi

Bone marrow (BM) assessment of minimal residual disease (MRD) is prognostic for survival in multiple myeloma (MM). BM is still hypocellular at month 1 post CAR-T, thus the value of MRD negative (MRDneg) status at this timepoint is unclear. We examined the impact of month 1 BM MRD status in MM patients who received CART at Mayo Clinic between 8/2016 and 6/2021. Among 60 patients, 78% were BM-MRDneg at month 1; and 85% (40/47) of these patients also had decreased to less than normal level of both involved and uninvolved free light chain (FLC < NL). Patients who achieved CR/sCR had higher rates of month 1 BM-MRDneg and FLC < NL. The rate of sustained BM-MRDneg was 40% (19/47). Rate of conversion from MRDpos to MRDneg was 5%(1/20). At month 1, 38%(18/47) of the BM-MRDneg were hypocellular. Recovery to normal cellularity was observed in 50%(7/14) with a median time to normalization at 12 months (range: 3–Not reached). Compared to Month 1 BM-MRDpos patients, patients who were BM-MRDneg had longer PFS irrespective of BM cellularity [PFS: 2.9 months (95% CI, 1.2-NR) vs. 17.5 months (95% CI, 10.4-NR), p < 0.0001]. Month 1 BM-MRDneg and FLC below normal were associated with prolonged survival. Our data support the continued evaluation of BM early post-CART infusion as a prognostic tool.

MAYO Clinic; BONE marrow; IMMUNOGLOBULIN light chains; PROGNOSIS; MULTIPLE myeloma

Blood Cancer Journal, 2023, Vol 13, Issue 1, p1

2044-5385

Academic Journal

10.1038/s41408-023-00820-y